Certolizumab pegol

mAbs

Volumn 2, Issue 2, 2010, Pages 137-147

  Goel, Niti ^a   Stephens, Sue ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Certolizumab pegol; Crohn disease; Methotrexate; PEGylated; Rheumatoid arthritis; TNF

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN F(AB) FRAGMENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CANADA; CLINICAL TRIAL; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; ERYSIPELAS; EUROPE; HEADACHE; HUMAN; INFECTION; NAUSEA; NONHUMAN; PNEUMONIA; PSORIASIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; TUBERCULOSIS; UNITED STATES;

ARTHRITIS, RHEUMATOID; CANADA; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; DRUG APPROVAL; EUROPEAN UNION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTHERAPY; MARKETING; POLYETHYLENE GLYCOLS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 77953660821     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.2.11271     Document Type: Short Survey

References (38)

1. Stakeholder Insight: Rheumatoid arthritis, biologics battle up the treatment algorithm. Data monitor 2006; 1-181.
2. Felfmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14:397-440.
3. Tracy D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumour necrosis mechanism of action: a comprehensive review. Pharmacol Ther 2008; 117:244-79.
4. Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 2003; 48:3308-19.
5. Van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when eternacept (Enbrel) has failed or vice vera: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003; 62:1195-8.
6. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56:13-20.
7. Keystone E, van der Heijde D, Mason DH, Landewé R, van Vollenhoven R, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis Rheum 2008; 58:3319-29.
8. Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68:797-804.
9. Fleischmann R, Shealy D. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis. Mol Interv 2003; 3:310-8.
10. Weir N, Athwal D, Brown D, Foulkes R, Kollias G, Nesbitt A, et al. A new generation of high-affinity humanized PEGylated Fab' fragment anti-tumour necrosis factor-α monoclonal antibodies. Therapy 2006; 3:535-45.
11. Nesbitt A, Fossati G, Bergin M Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other antitumour necrosis factor α agents. Inflamm Bowel Dis 2007; 13:1323-32.
12. Gramlick G, Fossati G, Nesbitt A, Henry AJ. Neutralization of soluble and membrane tumour necrosis factor α by infliximab, adalimumab or certolizumab pegol using p55 or p75 TNFα receptor bioassay. Gastroenterology 2006; 130:697.
13. Stephens S, Brown D, Nesbitt A, Foulkes B. Lack of placental transfer and accumulation in milk of an anti-TNF PEGylated Fab' fragment in rats. J Crohn's and Colitis 2007; 1:43.
14. Mahadevan U, Abreu MT. Certolizumab use in pregnancy: Low levels detected in cord blood. Gastroenterology 2009; 136:146.
15. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005; 10:1451-8.
16. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002; 54:531-45.
17. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999; 17:780-3.
18. Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab and infliximab in the inflamed paws of mice with collageninduced arthritis. J Immunol Methods 2009; 348:36-41.
19. Parton T, King L, van Asperen J, Heywood S, Nesbitt A. Investigation of the distribution and elimination of the PEG component of certolizumab pegol in rats. Journal of Crohn's and Colitis 2008; 2:26.
20. Parton T, King L, Parker G, Nesbitt A. The PEG moiety of certolizumab pegol is rapidly cleared from the blood of humans by the kidneys once it is cleaved from the Fab'. Ann Rheum Dis 2009; 68:189.
21. Fleischmann R, Vencovsky J, van Vollenhoven R, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68:805-11.
22. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason M, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357:228-38.
23. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Østergaard Thomsen O, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 537:239-50.
24. Sandborn WJ, Vermeire S, D'Haens GR, Colombel J-F, Fedorak RN, Spehlmann ME, et al. Welcome: a randomized, double-Blind, controlled trial comparing certolizumab pegol 400 mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate to severe Crohn's disease with secondary failure to infliximab. Gastroenterology 2009; 136:27-143.
25. Keystone E, Choy E, Kalden J, Klareskog L, Sany J, Smolen J, et al. CDP870, a novel, PEGylated humanised TNF-inhibitor is effective in treating the signs and symptoms of rheumatoid arthritis. Arthritis Rheum 2001; 44:2946.
26. Mease P. Certolizumab pegol for rheumatoid arthritis: effective in combination with methotrexate or as a monotherapy. Int J Clin Rheumatol 2009; 4:253-66.
27. Strand V, Mease P, Burmester GR, Nikai E, Coteur G, van Vollenhoven R, et al. Rapid and sustained improvements in health-related quality of life, fatigue and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther 2009; 11:170. Epub ahead of print.
28. Schiff M, Keystone EC, Kvien TK, Curtis JR, Emery P, Luijtens K, et al. DAS28(ESR) response at week 12 is predictive of long-term disease activity in rheumatoid arthritis patients treated with certolizumab pegol. Ann Rheum Dis 2009; 68:543.
29. Osterhaus JT, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPSRA). Arthritis Res Ther 2009; 11:73.
30. Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, et al. Certolizumab pegol with methotrexate improves home and workplace productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum 2009; 61:1592-600.
31. Keystone EC, Fleishmann R, Smolen J, Strand V, Landewe R, Combe B. Sustained efficacy of certolizumab pegol added to methotrexate (MTX) in the treatment of rheumatoid arthritis (RA): 2-year results from the RAPID 1 trial. Ann Rheum Dis 2009; 68:237.
32. Clinical Study Summary. CT Registry ID: NCT00544154. Available at http://www.clinicalstudyresults.org/documents/company-study-4348-0.pdf (08/12/2009).
33. Lichenstien G, Thomsen O, Schreiber S, Lawrance I, Hanauer S, Bloomfield R, et al. Long-term remission with certolizumab pegol in Crohn's disease over 3.5 years: results from the PRECiSE 3 study. Am J Gastroenterol 2009; 104:450.
34. Sandborn W, Schreiber S, Hanauer S, Colombel J-F, Bloomfield R, Lichtenstein G, et al. Long-term maintenance of remission with no dose escalation after reinduction with certolizumab pegol in patients with Crohn's disease exacerbation: 3-year results from the PRECiSE 4 Study. Am J Gastroenterol 2009; 104:448.
35. Colombel J-F, H'ebuterne X. Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the MUSIC clinical trial. Am J Gastroenterol 2008; 103:432.
36. Ortonne JP, Reich K, Sterry W, Terpstra I. Safety and efficacy (PASI 90 and global evaluation) of subcutaneous certolizumab pegol in patients with moderate to severe chronic plaque psoriasis: results from a double-blind, placebo-controlled trial. J Am Acad Dermatol 2008; 58:4.
37. Ortonne JP, Reich K, Keininger DL. Certolizumab pegol improved health-related quality of life in patients with psoriasis: data from a phase II study. J Am Acad Dermatol 2008; 58:121.
38. Schiff M, Sheikzadeh A, Formosa D, Domanska B, Morgan D. Validation of new pre-filled syringe for selfadministration in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68:561.